TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03230305

Intervention type: OTHER
Intervention: Ethnographic interview
Description: If a patient is invited to participate in the a clinical trial, inclusion's status (included or/not) will be sought.~* If included: an ethnographic interview will be held with patient (or his representant) who agreed to participate in the clinical trial, his family caregivers, his physician(s) in charge of him and the trial and, and clinical studies technician responsible for management.~* If not included, an ethnographic interview has offered to him, his caregivers, his physician(s) in charge of him and the trial and clinical studies technician responsible for management. In parallel, the reasons for non-inclusion are collected from a pre-established epidemiological questionnaire.~If a patient is not invited to participate,an ethnographic interview will be held with his physician(s) in charge of him and the clinical trial and with clinical studies technician responsible for management.The reasons for non-invitation will be collected from an epidemiological survey multiple choices.
Study: NCT02178683

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Tacrolimus and MMF.
Description: First dose of Tacrolimus is given day -4, this continues through day +365. First dose of MMF is given within 4 hours of stem cell infusion, this continues through day +365.
Study: NCT02581839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Medication: Zofran
Description: Zofran at 8mg orally. Given at the discretion of the treating physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Medication: Decadron
Description: decadron at 8mg orally. Given at the discretion of the treating physician
Study: NCT03475875

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A TEST Lens
Description: senofilcon A with new UV blocker investigational process

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A TEST Lens
Description: senofilcon A with new UV blocker investigational process

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A CONTROL Lens
Description: senofilcon A with new UV blocker standard process

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A CONTROL Lens
Description: senofilcon A with new UV blocker standard process
Study: NCT02923258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 20mg/m2/w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 100mg/m2/q3w

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: a total dose of 60Gy in 30fractions over 6 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: a total dose of 60Gy in 30fractions over 6 weeks
Study: NCT03059446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc
Description: Cenicriviroc immediate release tablets
Study: NCT00305890

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care will include routine medical care.
Study: NCT01845636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: A single acute dose of 1 mg of atropine nasal spray is administered to the nostril. The dose chosen reflects clinical doses typically used by Ear, Nose, and Throat (ENT) physicians.
Study: NCT00619151

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Top Hat
Description: Implant of CarboMedics Top Hat mechanical valve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regent
Description: Implant of the St. Jude Medical Regent mechanical valve
Study: NCT04001751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational yoga program
Description: Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yoga.
Study: NCT03448081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SNA-120
Description: SNA-120 (0.5%) active ointment
Study: NCT04374565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
Description: Pathogen reduced SARS-CoV-2 convalescent plasma (1-2 units; \~200 mL each for a total of 200-400mls) given preferably in one day, but allowable to be given over 2 days if clinical circumstances delay infusions in 1 day), with titer to be determined after the unit has been infused.
Study: NCT02015195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acetic Acid (5%)
Study: NCT03448081

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle Ointment
Study: NCT03625219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 40 mg (8 x 5mg tablets) for three consecutive days, then 30 mg (6 x 5mg tablets), 20 mg (4 x 5 mg tablets), 10 mg (2 x 5 mg tablets) and 5 mg (1 x 5 mg tablet) daily for two consecutive days for each dose level for a total of 11 days of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 tablets for 3 consecutive days; then 6 tablets, 4 tablets, 2 tablets, and 1 tablet daily for 2 consecutive days for each tablet count for a total of 11 days
Study: NCT02159092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Monetary incentive for the CM groups is contingent on a saliva cotinine reading that indicates smoking abstinence. Participants were assessed 10 times (Mondays/Thursdays) for abstinence from smoking waterpipe verified by saliva cotinine. The maximum monetary incentives this group can receive is $192.50. The CM groups followed an escalating schedule where: 1) the dollar amount of the incentive increases by $.50 as long as the participant is abstinent at each visit;; and 2) resets to the starting incentive ($14) if the participant was non-compliant at the previous visit, but is compliant at the current visit. Also, Participants were given $10 bonus for every three consecutive compliant visits.
Study: NCT02856789

Intervention type: OTHER
Intervention: Routine hemostasis tests
Description: Prothrombin Time (PT),Thrombin Time (TT), Activated Partial Thromboplastin Time (APTT), Fibrinogen, D-Dimers

Intervention type: OTHER
Intervention: Routine hemostasis tests
Description: Prothrombin Time (PT),Thrombin Time (TT), Activated Partial Thromboplastin Time (APTT), Fibrinogen, D-Dimers

Intervention type: OTHER
Intervention: Routine hemostasis tests
Description: Prothrombin Time (PT),Thrombin Time (TT), Activated Partial Thromboplastin Time (APTT), Fibrinogen, D-Dimers

Intervention type: OTHER
Intervention: Fibrin structure (FS)
Description: FS will be determined on STA-R® prototype at Percy and at Stago

Intervention type: OTHER
Intervention: Fibrin structure (FS)
Description: FS will be determined on STA-R® prototype at Percy and at Stago
Study: NCT02015195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate Slurry (50%)
Study: NCT02856789

Intervention type: OTHER
Intervention: Fibrin structure (FS)
Description: FS will be determined on STA-R® prototype at Percy and at Stago

Intervention type: OTHER
Intervention: Thromboelastography (TEG)
Description: Thromboelastography will be processed on TEG® at Percy

Intervention type: OTHER
Intervention: Thromboelastography (TEG)
Description: Thromboelastography will be processed on TEG® at Percy

Intervention type: OTHER
Intervention: Thromboelastography (TEG)
Description: Thromboelastography will be processed on TEG® at Percy

Intervention type: OTHER
Intervention: Specialized hemostasis tests
Description: Coagulation factors
Study: NCT04272905

Intervention type: OTHER
Intervention: Non-interventional study
Description: The participants will be asked to complete a questionnaire on their knowledge of, and attitudes towards the recording of patient care by patients or relatives/friends in the maternity unit. An investigator will be immediately available to facilitate completion of the survey and assist with understanding of the questions. The data recorded will be a mixture of nominal data (selections from a number of options using a tickbox) or ordinal (as above, but graded e.g. yes / yes with qualifiers / no). Free text will be coded and presented as nominal data or presented verbatim to illustrate points that arise.

Intervention type: OTHER
Intervention: Non-interventional study
Description: The participants will be asked to complete a questionnaire on their knowledge of, and attitudes towards the recording of patient care by patients or relatives/friends in the maternity unit. An investigator will be immediately available to facilitate completion of the survey and assist with understanding of the questions. The data recorded will be a mixture of nominal data (selections from a number of options using a tickbox) or ordinal (as above, but graded e.g. yes / yes with qualifiers / no). Free text will be coded and presented as nominal data or presented verbatim to illustrate points that arise.
Study: NCT01193725

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy (PE)
Description: Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET)
Description: Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist
Description: This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
Study: NCT04621123

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent anti-SARS-CoV-2 MBT plasma
Description: Subjects randomized to combination convalescent anti-SARS-CoV-2 MBT plasma plus SMT will undergo an ABO compatibility test and will receive a single infusion of 200 to 300 ml of ABO-compatible convalescent plasma

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Subjects randomized to placebo plus SMT will receive one infusion of 200 to 300ml of sterile saline solution 0.9%.
Study: NCT00994604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: broccoli sprout extract
Description: consumption of broccoli sprout extract for 2 weeks
Study: NCT00584103

Intervention type: DEVICE
Group type: OTHER
Intervention: Alpha P Control
Description: Subjects will be fitted with a terminal device with their current prosthesis and evaluated using the NYU trans-radial prosthesis checkout form.
Study: NCT02707094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biomodulator
Description: The Biomodulator is a type of very low frequency TENS known as pulsed electromagnetic field therapy (PEMF). Unlike TENS devices that deliver 1-80 milliamperes of electrical current, PEMF devices deliver short bursts of electrical microamperes (millionths of an ampere) to injured tissues without producing heat or interfering with nerve or muscle function. Micro-current levels between 20-500 microampere appear to be most effective at relieving pain and inflammation and promoting tissue healing by realigning the natural electrical balance that exists within the cells that has become disrupted due to injury.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care (Medication + Exercise)
Description: The study LP will prescribe an analgesic medication regimen based on the participant's needs. These medications may consist of Non-steroidal anti-inflammatory Drugs (NSAIDs) (ibuprofen, naproxen sodium, etc.), muscle relaxants (Flexeril, Robaxin, valium, etc.), non-narcotic analgesic medications (acetaminophen, aspirin, tramadol, etc.), or narcotic medications (Tylenol #3, Percocet, Vicodin, etc.) depending on the severity of their pain and co-morbid conditions. The RC will also provide instructions for LBP stretching and strengthening exercises. The following exercises will be recommended as a daily regimen: the partial curl, cat and camel, pelvic tilt, quadriceps, arm/leg raises,trunk rotation, single knee to chest stretch, standing hamstring stretch, and double knee to chest stretch.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care (Medication + Exercise)
Description: The study LP will prescribe an analgesic medication regimen based on the participant's needs. These medications may consist of Non-steroidal anti-inflammatory Drugs (NSAIDs) (ibuprofen, naproxen sodium, etc.), muscle relaxants (Flexeril, Robaxin, valium, etc.), non-narcotic analgesic medications (acetaminophen, aspirin, tramadol, etc.), or narcotic medications (Tylenol #3, Percocet, Vicodin, etc.) depending on the severity of their pain and co-morbid conditions. The RC will also provide instructions for LBP stretching and strengthening exercises. The following exercises will be recommended as a daily regimen: the partial curl, cat and camel, pelvic tilt, quadriceps, arm/leg raises,trunk rotation, single knee to chest stretch, standing hamstring stretch, and double knee to chest stretch.
Study: NCT00598962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Dosage dependent on clinical factors such as age, weight and patient-specific health status
Study: NCT02015195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Papain Slurry (70%)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ammonia (10%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine (4%)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isopropyl Alcohol (70%)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot Tap Water (40 degrees Celsius)
Study: NCT00598962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin/rifampin
Study: NCT02015195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment
Study: NCT02022423

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone counseling
Description: 4 months of weekly contact to update exercise prescription and discuss barriers and challenges to adherence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Description: 4 months of weekly contact to update exercise prescription and discuss barriers and challenges to adherence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based walking program
Description: Four-month Internet-based walking program consisting of weekly step count goals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based walking program
Description: Four-month Internet-based walking program consisting of weekly step count goals
Study: NCT02222129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine
Study: NCT03693365

Intervention type: PROCEDURE
Intervention: PEEP trial
Description: Positive end-expiratory pressure (PEEP) is increased from 5 to 10 cmH2O during one minute.
Study: NCT00854932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided decision making
Description: In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PDT values are within the normal range.
Study: NCT03578354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine
Description: an oral drug to be swallowed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: an oral drug to be swallowed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a masked placebo to be swallowed
Study: NCT02901717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mino-Lok
Description: Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic lock
Description: Standard of Care antibiotics appropriate for the infecting organism with an antibiotic lock solution using the same standard of care antibiotic delivered systemically. The antibiotic lock arm may include subjects with S. aureus, including methicillin-resistant S. aureus, vancomycin intermediate S. aureus, or vancomycin-resistant S. aureus; vancomycin resistant enterococci; Candida, Pseudomonas; other Gram negative organisms; or other organisms deemed to be of high virulence per the Investigator. The standard of care antibiotic will be determined by the investigator at the start of treatment.
Study: NCT03708003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Patients receive 6 cycles (cycle = 28 days) of ibrutinib monotherapy at the daily dose of 420 mg (3x 140 mg).~Venetoclax is added on ibrutinib treatment starting from cycle 7 as weekly dose ramp-up (20 mg, C7 day 1-7; 50 mg, C7 day 8-14; 100 mg, C7 day 15-21; 200 mg, C7 day 22-28; 400 mg, C8-31 day 1-28).~Venetoclax (400 mg d1-28) and ibrutinib (420 mg d1-28) continue until cycle 31. Depending on MRD-neg CR/CRi patients will continue the combination treatment (maintenance) or stop treatment (observation) up to 5 years after cycle 31.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is added on ibrutinib treatment starting from cycle 7 as weekly dose ramp-up (20 mg, C7 day 1-7; 50 mg, C7 day 8-14; 100 mg, C7 day 15-21; 200 mg, C7 day 22-28; 400 mg, C8-31 day 1-28).~Venetoclax (400 mg d1-28) and ibrutinib (420 mg d1-28) continue until cycle 31. Depending on MRD-neg CR/CRi patients will continue the combination treatment (maintenance) or stop treatment (observation) up to 5 years after cycle 31.
Study: NCT02015195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment
Study: NCT03806595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% Injectable Solution
Description: The Barre method of intranasal administration will be used to instil 1mL of lidocaine 2% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: The Barre method of intranasal administration will be used to instil 1mL of saline 0.9% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
Study: NCT01187212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine/Cisplatin + Sorafenib
Description: Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine/Cisplatin
Description: Capecitabine 1000 milligram (mg) / m² po bid (D1-14) Cisplatin 80 mg / m² IV Day 1
Study: NCT01781026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Single arm trial
Study: NCT01396408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: 50 mg PO daily for 28 days, q 6 weeks (1 cycle=6 weeks or 42 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temsirolimus
Description: 25 mg IV weekly (Days 1, 8, 15, 22, 29, 36), q 6 weeks (1 cycle=6 weeks or 42 days)
Study: NCT03366740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GB mixed full strength rice suji
Description: On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get the Green banana mixed full strength rice suji The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full strength rice suji Alone
Description: On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get full strength rice suji alone.~The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3/4th strength rice suji
Description: On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get 3/4th strength rice suji.~The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure.
Study: NCT01052597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcumin
Description: Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: curcumin
Description: Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months
Study: NCT00538382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: A 200 mg dose of orally administered artesunate at the beginning of a 48-hour clinical sampling period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: A 200 mg dose of orally administered artesunate at the beginning of a 48-hour clinical sampling period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: A 200 mg dose of orally administered artesunate at the beginning of a 48-hour clinical sampling period.